UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.68) by 17.65 percent. This is a 11.11 percent decrease over losses of $(0.72) per share from the same period last year. The company reported quarterly sales of $24.57 million which missed the analyst consensus estimate of $25.63 million by 4.17 percent. This is a 4.40 percent increase over sales of $23.53 million the same period last year.